- AmbioPharm announces a $28 million investment to expand its Shanghai manufacturing site by 70,000 square feet.
- The expansion will enhance the company’s peptide manufacturing capabilities, enabling an output of over 8 metric tons of crude peptide annually.
AmbioPharm, a U.S.-based pharmaceutical services company, has announced the groundbreaking of a $28 million expansion at its Shanghai site. The project, set to add 70,000 square feet of manufacturing capacity, is designed to meet growing global demand for peptide therapeutics. This new facility is expected to produce over 8 metric tons of crude peptide annually, with advanced capabilities in solid-phase and liquid-phase peptide synthesis.
Scheduled for completion in the second half of 2025, the expansion will include multiple 1000L to 3000L equipment lines for fragment-based peptide synthesis. The additional production capacity will support both downstream peptide purification at the Shanghai site and AmbioPharm’s U.S. facility in North Augusta, South Carolina.
“This expansion underscores our commitment to China and its role in our global operations,” said Brian Gregg, CEO of AmbioPharm. He added that the new capabilities would enhance the company’s ability to serve its global customer base.